Stephen Maier, MD
Orthopaedic Surgery · Essex, CTNPI 1538659818
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $23,703 with a category attached, or 84.4%. Arthrex accounts for 88.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $21,397 and has fallen 98.1% since, to $413 in 2025.
Across 45 payments — averaging $526.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$21K
- Kairos Surgical Inc$2K
- Stryker$488
- Smith+Nephew$220
- Vericel Corporation$182
- Polaris Technology Solutions LLC$125
- plus $111 from 3 others
What the payments were for
- Grants$20,00084%
- Travel & lodging$8213%
- Food & beverage$1,3606%
- Education$1,5226%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 18 | $21,033 |
| Kairos Surgical Inc | 2 | $1,543 |
| Stryker | 13 | $488 |
| Smith+Nephew | 3 | $220 |
| Vericel Corporation | 3 | $182 |
| Polaris Technology Solutions LLC | 1 | $125 |
| Johnson & Johnson | 3 | $75 |
| Vertex | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,703 in reported general payments places this provider in the 80th percentile of 273 orthopaedic surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 43 | $70 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Essex
- Andrew ZhangEssex$53K
- Peter WhangNew Haven$1.8M
- Paul SethiGreenwich$1.5M
- James YueShelton$1.3M
- Robert DeveneyDanbury$907K
- James PaceFarmington$721K
- Isaac MossFarmington$676K
- David FrumbergNew Haven$288K
- John KeggiMiddlebury$264K
- Lauren GeaneyFarmington$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.